Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 07:28 PM. | Search:

» StockRants Stock Forum » Public Stock Forums » US Penny Stock Picks » Strong Buy: AYTU (MC $13 M) (Cash $15 M) MEGA Drug launch in July ($2+BILLION Market )



Reply
 
Thread Tools Search this Thread
Old 05-26-2016, 01:27 PM   Nav to Top  #1
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 106
Reputation: 36
Biohero is on a distinguished road
Default AYTU (MC $13 M) (Cash $15 M) MEGA Drug launch in July ($2+BILLION Market )

Here is an undiscovered Stock with Monster Upside Potential which just trading at cash level . Aytu Biosciences bought US Rights to Natesto the only approved testosterone nasal gel which targets a $2+ BILLION Market which they start selling in July . The Company has another 3 Products on the Market and another One Big drug ready for Phase 3 . AYTU has a ridiculous Market Cap of just $14 Million which is below the Cash balance of $15 Million means you get the Company and Products for free . The Stock has minumum ipside Potential of 700% .


In April, AYTU signed an exclusive license agreement for the U.S. commercial rights to Natesto® (testosterone) Nasal Gel. Natesto is the first and only nasal formulation of testosterone approved by the U.S. Food and Drug Administration (FDA) as a replacement therapy for men diagnosed with hypogonadism (low testosterone, or “Low T”). Aytu anticipates further expanding its current urology-centric sales force and initiating its promotion of Natesto into the $2 billion U.S. testosterone replacement market in July 2016.



Aytu Bioscience (AYTU)

Market Cap: $13.5 Million
Cash: $15 Million
Price: $0.30

Shares Out: 44.86 Million


Marketed Products:

PRIMSOL : Only FDA-approved trimethoprim oral solution; indicated for urinary tract infections

ProstaScint : Only FDA-approved imaging agent for prostate cancerdetection and staging

MIOXSYS : CE Marked in vitro diagnostic device for male infertility , Single FDA study pending


Acquired Exclusive U.S. Rights to Natesto April 2016 (US Market Launch July)

•Only FDA-approved, nasally-administered testosterone; indicated for hypogonadism
•Approved for use WITHOUT black box warning related to partner transference

ZERTANE :Phase 3-ready, effective first-in-class oral treatment for premature ejaculation


Presentation May 2016
http://aytubio.com/downloads/Aytu-Co...e-Overview.pdf


Aytu BioScience Initiates Commercial Expansion to Support July 2016 Launch of Natesto®
Aytu BioScience Initiates Commercial Expansion to Support July 2016 Launch of Natesto® - Yahoo Finance



Insider Buying:

May 6, 2016 DISBROW JOSHUA R. Officer direct Buy 0.40 250,000

May 6, 2016 DISBROW JARRETT Officer direct Buy 0.40 250,000

May 6, 2016 DOCKERY CARL Director indirect Buy 0.40 5,000,000

Jan 20, 2016 DISBROW JOSHUA R. Officer direct Buy 0.65 153,846

Jan 20, 2016 DISBROW JARRETT Officer direct Buy 0.65 153,846
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 05-27-2016, 10:09 AM   Nav to Top  #2
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 106
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Aytu is definitely oneof the cheapest Biotechs out there but this will change quickly once investors discover this Goldmine .GL

AYTU – Expanding Men’s Urology Portfolio...... By Zacks Small Cap Research
May 25, 2016 4:30 PM

AYTU – Expanding Men’s Urology Portfolio - Yahoo Finance

VALUATION AND RECOMMENDATION

We are initiating coverage on Aytu Bioscience (AYTU) with a Buy rating and a price target of $1.30/share.
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 11-14-2016, 05:42 AM   Nav to Top  #3
trderlife77
Junior Trader
 
trderlife77's Avatar
 
Join Date: Nov 2016
Location: Canada
Posts: 4
Favorites: cat,dog.buffalo
Rep Power: 36
Reputation: 10
trderlife77 is on a distinguished road
Default

Look at the income statement and balance sheet for TKAT possibly the best financials in the entire OTC
trderlife77 is offline   Rate this post Yes | No Reply With Quote
Reply

Similar Threads
Thread Thread Starter Forum Replies Last Post
Strong Buy: STDY (MC $ 35M) NDA filing in 2H for MEGA Orphan Drug = Lifetime Opportunity Biohero US Stock Picks 4 04-07-2016 03:29 AM
Strong Buy: BNC.TO (MC $42 M)(Cash $12 M) Approval For Bladder Cancer Drug soon Biohero Canadian Stock Picks 7 11-02-2015 10:28 AM
Strong Buy: BLUSF (MC $17 M) (Cash $16M ) Big Rare Disease Drug in Phase 3 Close to End = 1000% Biohero US Penny Stock Picks 0 01-28-2014 09:20 AM
Billion US Dollar Cash deposit by OTC BGMO notriousinvestor US Penny Stock Picks 0 02-09-2013 09:29 PM
Watch: SAFC enters $7 Billion US market with breakthrough technology! ddyson73 US Penny Stock Picks 0 11-12-2012 06:51 AM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On